Roche Holdings

• Optimal Opportunities

  By Ed McCarthy, CFP  |  February 22, 2013

  While Actavis (ACT) narrowed its 2013 guidance expectations in the wake of an unexpected Concerta approval, the company is still poised to post close to 30% EPS growth and potentially double-digit annual EPS growth through 2016.

• Health Care/Biotech: A Good Prognosis

  By Ed McCarthy, CFP  |  September 1, 2011

  Companies offering advanced medical technology and pharmaceuticals continue to show strong revenue and profit growth.

• Changing Shades of Blue

  By James J. Green, AdvisorOne  |  July 1, 2009

  As of December 31, 2008, the top five holdings in Massachusetts Investors Trust, which this year celebrates the 85th anniversary of its founding, were the...

• Positive Outlook

  By Staff Writer  |  March 1, 2007

  Companies in a variety of biotech and health-care sectors should see sales and development progress in 2007, analysts say. Edward A. Tenthoff Piper Jaffray & Co. 212-284-9403 edward.a.tenthoff@pjc.com Area of...

• Blending In Nicely

  By Staff Writer  |  November 1, 2006

  Large-cap blend funds seek to combine the best of both worlds--growth-oriented stocks which provide high earnings growth, tempered by value-oriented issues which offer the stability...